Clinical Trials Browser

Primary Central Nervous System Lymphoma (PCNSL) × Nivolumab × 90 days × Clear all

NCT04401774 2026-01-27

Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

Phase 2 Completed

Primary Central Nervous System Lymphoma (PCNSL)